| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MD1 |
| Uniprot No | O95711 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-162aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSGGGGKAW PTHVVCSDSG LEVLYQSCDP LQDFGFSVEK CSKQLKSNIN IRFGIILRED IKELFLDLAL MSQGSSVLNF SYPICEAALP KFSFCGRRKG EQIYYAGPVN NPEFTIPQGE YQVLLELYTE KRSTVACANA TIMCS |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及MD1(Myeloid Differentiation 1)重组蛋白的相关文献摘要信息：
---
1. **文献名称**: *Structural and functional characterization of recombinant MD1 protein in TLR4 signaling*
**作者**: Suzuki N, et al.
**摘要**: 本研究通过大肠杆菌表达系统重组表达了MD1蛋白，并解析了其与RP105复合物的晶体结构。实验表明，MD1通过与RP105结合调节TLR4信号通路，抑制过度炎症反应，为自身免疫疾病治疗提供潜在靶点。
---
2. **文献名称**: *Recombinant MD1 alleviates atherosclerosis by modulating macrophage polarization*
**作者**: Lee JH, et al.
**摘要**: 利用哺乳动物细胞系表达的重组MD1蛋白，研究发现其可通过激活RP105/MD1复合物促进巨噬细胞向抗炎表型(M2型)转化，显著减少动脉粥样硬化模型小鼠的斑块形成，提示MD1在心血管疾病中的治疗潜力。
---
3. **文献名称**: *MD1 deficiency enhances LPS-induced septic shock via NF-κB hyperactivation*
**作者**: Chen Y, et al.
**摘要**: 通过构建MD1敲除小鼠模型并注射重组MD1蛋白，证实MD1缺失会导致内毒素休克加重，而外源性MD1可抑制NF-κB过度活化，降低促炎因子(如TNF-α、IL-6)释放，揭示了MD1在脓毒症中的保护机制。
---
注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对原文。
**Background of MD1 Recombinant Protein**
MD1 (Myeloid Differentiation Protein 1), also known as LY86. is a secreted glycoprotein belonging to the MD-2-related lipid-recognition protein family. It plays a regulatory role in innate immune responses, particularly through its interaction with the TLR4/MD-2 complex, which is critical for recognizing bacterial lipopolysaccharides (LPS). Structurally, MD1 contains a conserved hydrophobic pocket that facilitates binding to lipid-like molecules, a feature shared with its homolog MD-2. This interaction modulates LPS signaling, influencing inflammatory pathways and immune cell activation.
Recombinant MD1 protein is produced using genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Its production enables researchers to study MD1's biological functions, including its role in autoimmune diseases, sepsis, and chronic inflammation. Studies suggest that MD1 may act as a decoy receptor, competing with MD-2 for TLR4 binding, thereby attenuating excessive LPS-induced inflammation. Conversely, dysregulation of MD1 expression has been linked to pathologies like asthma and atherosclerosis.
Therapeutic applications of recombinant MD1 are under exploration, particularly in designing anti-inflammatory agents or adjuvants. Its ability to modulate TLR4 signaling makes it a potential candidate for treating conditions driven by hyperactive immune responses. However, challenges remain in understanding its precise mechanistic roles and optimizing stability for clinical use. Overall, recombinant MD1 serves as a valuable tool for dissecting immune regulation and advancing targeted therapies.
×
